Stock Analysis

ArcticZymes Technologies Third Quarter 2024 Earnings: Misses Expectations

OB:AZT
Source: Shutterstock

ArcticZymes Technologies (OB:AZT) Third Quarter 2024 Results

Key Financial Results

  • Revenue: kr24.1m (down 23% from 3Q 2023).
  • Net loss: kr1.56m (down by 126% from kr6.06m profit in 3Q 2023).
  • kr0.03 loss per share (down from kr0.12 profit in 3Q 2023).
earnings-and-revenue-growth
OB:AZT Earnings and Revenue Growth November 8th 2024

All figures shown in the chart above are for the trailing 12 month (TTM) period

ArcticZymes Technologies Revenues and Earnings Miss Expectations

Revenue missed analyst estimates by 15%. Earnings per share (EPS) was also behind analyst expectations.

Looking ahead, revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 38% growth forecast for the Biotechs industry in Norway.

Performance of the Norwegian Biotechs industry.

The company's shares are down 21% from a week ago.

Risk Analysis

You still need to take note of risks, for example - ArcticZymes Technologies has 3 warning signs we think you should be aware of.

New: Manage All Your Stock Portfolios in One Place

We've created the ultimate portfolio companion for stock investors, and it's free.

• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks

Try a Demo Portfolio for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

About OB:AZT

ArcticZymes Technologies

A life sciences company, develops, manufactures, and commercializes recombinant enzymes for use in molecular research, in vitro diagnostics, and biomanufacturing in Norway, Germany, Lithuania, France, Italy, rest of Europe, the United States, and internationally.

Flawless balance sheet with reasonable growth potential.